Bioventus Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BVS | TCMD | BBNX | ECOR | TLSI | 0853.HK | |
|---|---|---|---|---|---|---|
| Market cap | 781.98M | 608.87M | 921.52M | 75.73M | 239.53M | 11.62B |
| P/E (TTM) | 14.1 | 26.4 | — | — | — | — |
| Forward P/E | 12.5 | 18.5 | -7.8 | -15.3 | -15.6 | 23.3 |
| Price/book | 3.3 | 2.7 | 2.3 | -27.1 | 36.4 | 1.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +48.31% | +2.35% | −43.04% | +52.53% | −21.80% | −46.33% |
| Today | +4.34% | +9.69% | +12.25% | +16.18% | +11.78% | 0.00% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All BVS news ›Bioventus expects 2026 revenue of $590M-$595M while reaffirming adjusted EPS of $0.75-$0.79
Bioventus Q3 2026 earnings: revenue guidance cut on BGS weakness, EPS reaffirmed, and Q4 acceleration expected. Earnings Call Insights: Bioventus (BVS) Q3 2026 CEO Robert Claypoole framed Q3 as continued momentum while emphasizing that the…
Bioventus Inc. (BVS) Q3 2026 Earnings Call Transcript
Bioventus Inc. (BVS) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST David Crawford - Vice President of Investor Relations & TreasurerRobert Claypoole - President, CEO & DirectorMark Singleton - Senior VP & CFO Good afternoon, and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.